全球重组人类生长激素 (RHGH) 市场 – 行业趋势和 2031 年预测

重组人类生长激素 (RHGH) 市场分析和规模

重组人类生长激素 (RHGH) 市场正经历全球显著增长，这主要得益于几个关键因素。主要驱动因素之一是生长激素缺乏症 (GHD) 和其他生长障碍的患病率不断上升，这导致对 RHGH 疗法的需求不断增长。此外，RHGH 长效制剂的开发提高了患者的依从性和便利性，进一步推动了市场增长。医疗保健支出的增加，尤其是在发展中国家，正在改善患者获得 RHGH 疗法的机会。此外，探索 RHGH 疗法的新适应症，例如提高老年人的肌肉质量或提高运动成绩，正在开辟新的市场机会。

2023 年全球重组人类生长激素 (RHGH) 市场规模价值 16.1 亿美元，预计到 2031 年将达到 35.3 亿美元，2024 年至 2031 年预测期内的复合年增长率为 10.30%。除了对市场价值、增长率、细分、地理覆盖范围和主要参与者等市场情景的见解外，Data Bridge Market Research 策划的市场报告还包括深度专家分析、患者流行病学、管道分析、定价分析和监管框架。

报告范围和市场细分       

Market Definition

Recombinant Human Growth Hormone (RHGH) is a synthetic form of the human growth hormone (HGH), which is naturally produced by the pituitary gland in the brain. RHGH is produced using recombinant DNA technology, where the gene for human growth hormone is inserted into host cells, such as bacteria or yeast, which then produce the hormone. RHGH is used therapeutically to treat growth hormone deficiency (GHD) in children and adults, and other conditions.   

Recombinant Human Growth Hormone (RHGH) Market Dynamics

Drivers

• Growing Prevalence of Growth Disorders 

The rising incidence of growth disorders, including growth hormone deficiency (GHD) and Turner syndrome, can significantly impact an individual's quality of life, leading to physical and developmental challenges. With increasing awareness of these disorders and improving diagnostic techniques, more patients are being identified and seeking treatment. This is expected to continue driving the demand for RHGH therapies, especially as the global population ages and the prevalence of these disorders rises, driving the market growth.        

• Development of Long-Acting Formulations

The development of long-acting formulations of RHGH therapies has the potential to revolutionize the market by improving patient compliance and convenience. Currently, frequent recombinant human growth hormone injections are required, which can be cumbersome for patients and may lead to non-compliance. Long-acting formulations offer the advantage of fewer injections, reducing the treatment burden for patients. This could lead to better treatment outcomes and increased patient satisfaction, ultimately driving market growth. As research in this area continues and more long-acting formulations become available, the market for RHGH therapies is expected to expand significantly, catering to a larger patient population.       

Opportunities

• RHGH Therapies for New Indications

The exploration of recombinant human growth hormone therapy for new indications beyond traditional uses in addition to treating growth disorders, such as growth hormone deficiency (GHD) and Turner syndrome, RHGH therapies are being investigated for their potential to improve muscle mass in the elderly and enhance athletic performance. These new indications are based on the role of growth hormone in promoting muscle growth and repair. As research in this area progresses and new applications are discovered, the market for RHGH therapies is expected to expand, catering to a broader range of patients and needs.     

• Rising Healthcare Expenditure

Rising healthcare costs, particularly in developing countries, are significantly improving access to recombinant human growth hormone (RHGH) therapies for patients. As economies develop and healthcare systems expand, there is a greater focus on addressing the healthcare needs of the population, including the treatment of growth disorders. This increased spending is enabling more patients to afford RHGH therapies, thereby driving market growth. In addition, as healthcare infrastructure improves and awareness about growth disorders increases, the demand for RHGH therapies is expected to rise further, supported by the growing healthcare budgets in these regions.

Restraints/Challenges

• High Cost of Treatment    

Factors such as dosage, administration frequency, and treatment duration result in changing recombinant human growth hormone costs. In many developing countries, the high cost of these therapies places them out of reach for a large portion of the population. In addition, even in developed countries with robust healthcare systems, patients without adequate insurance coverage may struggle to afford these treatments. As a result, the high cost of RHGH therapies can limit access to these potentially life-changing treatments for many individuals.   

• Safety Concerns Regarding RHGH

Surgeries While RHGH therapies are generally considered safe and effective when used appropriately, there are potential risks associated with their use. The disadvantages of recombinant human growth hormone include the development of diabetes, increased intracranial pressure, and potential long-term effects on growth and development. Safety concerns can cause both patients and healthcare providers to hesitate in using RHGH therapies, particularly in cases where the benefits may not outweigh the risks and can be a major challenge for market growth.

本市场报告详细介绍了最新发展、贸易法规、进出口分析、生产分析、价值链优化、市场份额、国内和本地市场参与者的影响，分析了新兴收入领域的机会、市场法规的变化、战略市场增长分析、市场规模、类别市场增长、应用领域和主导地位、产品批准、产品发布、地域扩展、市场技术创新。如需获取更多市场信息，请联系 Data Bridge Market Research 获取分析师简报，我们的团队将帮助您做出明智的市场决策，实现市场增长。

最新动态

• 2023 年 8 月，FDA 批准了 Opko Health, Inc. 和辉瑞公司针对生长激素缺乏症儿童的每周一次 somatrogon，展示了市场主要参与者的战略进步。这种长效注射剂 Somatrogon-ghla (Ngenla) 在提高年度身高增长速度方面已证明不逊于生长激素，这一点已由 3 期试验数据证明
• 2023 年 5 月，诺和诺德在人类生长激素治疗市场取得了重大进展，欧洲药品管理局积极推荐每周一次的 Sogroya 用于三岁以上儿童，针对青少年生长激素缺乏和发育障碍。这使 Sogroya 成为一种有前途的替代疗法，标志着诺和诺德战略扩张努力的重要里程碑

重组人类生长激素 (RHGH) 市场范围

市场根据应用、给药途径和分销渠道进行细分。这些细分市场之间的增长情况将帮助您分析行业中增长缓慢的细分市场，并为用户提供有价值的市场概览和市场洞察，帮助他们做出战略决策，确定核心市场应用。

应用

• 生长激素缺乏
• 特纳综合征
• 特发性身材矮小
• 普拉德威利综合征
• 其他的

给药途径

• 静脉
• 肌肉注射
• 皮下
• 口服

最终用途

• 医院药房
• 零售药店
• 诊所
• 其他药房

重组人类生长激素 (RHGH) 市场区域分析/见解

对市场进行了分析，并按上述国家、应用、给药途径和分销渠道提供了市场规模洞察和趋势。

市场覆盖的国家包括美国、加拿大、墨西哥、德国、法国、英国、荷兰、瑞士、比利时、俄罗斯、意大利、西班牙、土耳其、欧洲其他地区、中国、日本、印度、韩国、新加坡、马来西亚、澳大利亚、泰国、印度尼西亚、菲律宾、亚太其他地区、沙特阿拉伯、阿联酋、南非、埃及、以色列、中东和非洲其他地区、巴西、阿根廷和南美洲其他地区。

由于老年人口的增长、现有市场领导者的存在以及旨在开发创新重组人类生长激素疗法的持续研究，北美预计将占据市场主导地位。  

由于人口增长和民众对医疗保健意识增强等因素，预计亚太地区将在预测期内实现显着增长。此外，该大陆的经济状况有所改善，从而促进了医疗保健基础设施的进步。

报告的国家部分还提供了影响单个市场因素和国内市场监管变化，这些因素和变化会影响市场的当前和未来趋势。下游和上游价值链分析、技术趋势和波特五力分析、案例研究等数据点是用于预测单个国家市场情景的一些指标。此外，在提供国家数据的预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的激烈或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。

医疗保健基础设施增长安装基础和新技术渗透

该市场还为您提供每个国家/地区资本设备医疗支出增长、市场上不同类型产品的安装基数、使用生命线曲线的技术影响以及医疗监管情景的变化及其对市场的影响的详细市场分析。数据适用于 2016-2021 年的历史时期。

竞争格局和重组人类生长激素 (RHGH) 市场份额分析

市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对市场的关注有关。

市场上的一些主要参与者包括：

• SottoPelle（美国）
• 诺华公司（瑞士）
• Orion Pharma AB（瑞典）
• 完整生活健康中心（美国）
• BioTE Medical, LLC（美国）
• 默克集团（德国）
• 辉瑞公司（美国）
• TherapeuticsMD, Inc.（美国）
• Papillon Medical（加拿大）
• 联合药房（美国）
• Noven Pharmaceuticals, Inc.（美国）
• GEA 集团股份公司（德国）
• 诺和诺德公司（丹麦）
• 基因科学制药股份有限公司 (中国)
• Actiza Pharmaceutical Private Limited（印度）
• Defy Medical（美国）
• Neuva Aesthetics（美国）
• ZRT实验室（美国）
• 拜耳公司（德国）
• 艾尔建（爱尔兰）

SKU-52652